Argenica Therapeutics' AI-Driven Reanalysis of Phase 2 Stroke Trial Shows Commercially Meaningful Benefit, Says Euroz Hartleys

BUZZ-Australia's Argenica Therapeutics jumps on meeting FDA condition

Argenica Therapeutics Ltd-Non-Executive Director Retirement

New Results From Argenica Therapeutics' ARG-007 Second Phase Trial Show 'Encouraging' Signs, Euroz Hartleys Says

Argenica Therapeutics ARG-007 Phase 2 Trial Shows Strong Safety, Efficacy in High-Risk Group, Euroz Hartleys Says

BRIEF-Argenica Therapeutics Seeks Trading Halt

Argenica Therapeutics - Seeks Trading Halt Pending Announcement on Phase 2 Arg-007 Stroke Trial Results

Argenica Therapeutics Ltd - FY Loss Attributable a$7.2 Mln

Argenica Therapeutics - FY Revenues From Ordinary Activities a$3.7 Mln

Argenica Therapeutics Receives Full Clinical Hold Letter from FDA Regarding Investigational New Drug Application

Argenica Therapeutics Ltd-Argenica Appoints Vice President of Regulatory Affairs

A 5% Reduction in Brain Cell Injury Volume Significant for Argenica's Acute Ischemic Stroke Treatment Candidate, Euroz Hartleys Says

Cleansing Notice-AGN.AX

Application for quotation of securities - AGN-AGN.AX

BUZZ-Australia's Argenica Therapeutics rises on funding from federal government